Paper Details

  1. Home
  2. Paper Details

Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer.

Author: , BardetStéphane, BroseMarcia S, CapdevilaJaume, EliseiRossella, FührerDagmar, GaoMing, HadouxJulien, HoffAna O, HuMimi I, IsaevPavel, JarzabBarbara, KeamBhumsuk, KopeckovaKaterina, LinBoris, LinYan, MaedaPatricia, RobinsonBruce G, ShermanEric J, SinghRavinder, SoldatenkovaVictoria, TaharaMakoto, WadsleyJonathan, WirthLori J, WrightJennifer

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Selpercatinib resulted in superior progression-free survival and treatment failure-free survival compared to cabozantinib or vandetanib in patients with advanced RET-altered medullary thyroid cancer.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced METHODS: We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2309719

データ提供：米国国立医学図書館（NLM）

Selpercatinib: A New Oasis in the Treatment of RET-Mutant Medullary Thyroid Cancer

Medullary thyroid cancer, like a formidable sand dune, can be a challenging foe. This study, like a skilled caravan leader seeking a safe passage through treacherous terrain, investigates the effectiveness of selpercatinib, a new drug, in treating advanced RET-mutant medullary thyroid cancer. The study, a phase 3 randomized trial, compared selpercatinib to standard treatment options. The researchers discovered that selpercatinib significantly improved progression-free survival and treatment failure-free survival compared to cabozantinib or vandetanib. This research offers a promising new treatment option for patients with RET-mutant medullary thyroid cancer, a discovery as valuable as finding a hidden oasis in the desert.

A New Hope for Medullary Thyroid Cancer Patients

This study provides a beacon of hope for individuals battling RET-mutant medullary thyroid cancer. The positive results suggest that selpercatinib could significantly improve outcomes for these patients, a discovery as momentous as the first camel caravan successfully traversing the Sahara Desert.

Navigating the Path Towards a Cure

This research is a significant step towards developing more effective treatments for medullary thyroid cancer. The effectiveness of selpercatinib offers a promising avenue for research and development, paving the way towards a future where this disease is no longer a formidable threat.

Dr. Camel's Conclusion

This study, like a well-stocked caravan ready to embark on a long journey, holds great promise for the treatment of RET-mutant medullary thyroid cancer. Selpercatinib's effectiveness in improving survival outcomes is a valuable breakthrough, offering hope for a brighter future for patients facing this challenging disease.

Date :
  1. Date Completed 2023-11-20
  2. Date Revised 2023-11-20
Further Info :

Pubmed ID

37870969

DOI: Digital Object Identifier

10.1056/NEJMoa2309719

Related Literature

Article Analysis
・Effects of selpercatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.